Medullary thyroid cancer: A retrospective analysis of a cohort treated at a single tertiary care center between 1970 and 2005

Thyroid

Volumn 17, Issue 6, 2007, Pages 549-556

  Grozinsky Glasberg, Simona ^a,c   Benbassat, Carlos A ^a,c   Tsvetov, Gloria ^a   Feinmesser, Rafael ^a,c   Peretz, Hava ^b,c   Shimon, Han ^a,c   Lapidot, Mordechai ^a,c  

^a RABIN MEDICAL CENTER   (Israel)

^b TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITONIN;

ADULT; ARTICLE; CALCITONIN BLOOD LEVEL; CANCER REGRESSION; COHORT ANALYSIS; FEMALE; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; ONCOGENE RET; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; SURVIVAL RATE; SURVIVAL TIME; THYROID MEDULLARY CARCINOMA; THYROIDECTOMY; TUMOR VOLUME;

ADULT; AGED; CALCITONIN; CARCINOEMBRYONIC ANTIGEN; CARCINOMA, MEDULLARY; COHORT STUDIES; FEMALE; HUMANS; ISRAEL; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SURVIVAL RATE; THYROID NEOPLASMS;

EID: 34447506199     PISSN: 10507256     EISSN: None     Source Type: Journal    
DOI: 10.1089/thy.2006.0229     Document Type: Article

References (39)

1. Hazard JB, Hawk WA, Crile GJ 1959 Medullary (solid) carcinoma of the thyroid: a clinicopathologic entity. J Clin Endocrinol Metab 19:152-161.
2. Ball DW, Baylin SB, De Bustros AC 2000 Medullary thyroid carcinoma. In: Braverman LE, Utiger RD (eds) Werner and Ingbar's The Thyroid. 8th ed. Lippincott Williams & Wilkins, Philadelphia, pp 930-943.
3. Orlandi F, Caraci P, Mussa A, Saggiorato E, Pancani G, Angeli A 2001 Treatment of medullary thyroid carcinoma: an update. Endocr Relat Cancer 8:135-147.
4. Leboulleux S, Baudin E, Travagli J, Schlumberger M 2004 Medullary thyroid carcinoma. Clin Endocrinol 61:299-310.
5. Kaltsas GA, Besser GM, Grossman AB 2004 The diagnosis and medical management of advanced neuroendocrine tumors. Endocr Rev 25:458-511.
6. Mirallie E, Vuillez JP, Bardet S, Frampas E, Dupas B, Ferrer L, Faivre-Chauvet A, Murat A, Charbonnel B, Barbet J, Goldenberg DM, Chatal JF, Kraeber-Bodere F 2005 High frequency of bone/bone marrow involvement in advanced medullary thyroid cancer. J Clin Endocrinol Metab 90:779-788.
7. Brierley J, Tsans R, Simpson WJ, Gospodarowicz M, Sutcliffe S, Panzarella T 1996 Medullary thyroid cancer: analysis of survival and prognostic factors and the role of radiation therapy in local control. Thyroid 6:305-309.
8. Rougier P, Parmentier C, Laplanche A, Lefevre M, Travagli JP, Caillou B, Schlumberg M, Lacour J, Tubiana M 1983 Medullary thyroid carcinoma: prognostic factors and treatment. Int J Radiat Oncol Biol Phys 9:161-169.
9. Chow SM, Chan JKC, Tiu SC, Choi KL, Tang DLC, Law SCK 2005 Medullary thyroid carcinoma in Hong Kong Chinese patients. Hong Kong Med J 11:251-258.
10. Hyer SL, Vini L, A'Hern R, Harmer C 2000 Medullary thyroid cancer: multivariable analysis of prognostic factors influencing survival. Eur J Surg Oncol 26:686-690.
11. Saad MF, Ordonez NG, Rashid RK, Guido JJ, Hill CS Jr, Hickey RC, Samaan NA 1984 Medullary carcinoma of the thyroid. A study of clinical features and prognostic factors in 161 patients. Medicine (Baltimore) 63:319-342.
12. Kebebew E, Ituarte P, Siperstein A, Duh Q, Clark O 2000 Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and comparison of staging systems. Cancer 88:1139-1148.
13. Peretz H, Luboshitsky R, Baron E, Biton A, Gershoni R, Usher S, Grynberg E, Yakobson E, Graff E, Lapidot M 1997 Cys618Arg mutation in the RET proto-oncogene associated with familial medullary thyroid carcinoma and maternally transmitted Hirschsprung's disease suggesting a role for imprinting. Hum Mutat 10:155-159.
14. Pigny P, Bauters C, Wemeau J-L, Houcke ML, Crepin M, Caron P, Giraud S, Calender A, Buisine M-P, Kerckaert J-P, Porchet N 1999 A novel 9-base pair duplication in RET exon 8 in familial medullary thyroid carcinoma. J Clin Endocrinol Metab 84:1700-1704.
15. Mulligan LM, Eng C, Attie T, Lyonnet S, Marsh DJ, Hyland VJ, Robinson BG, Frilling A, Verellen-Dumoulin C, Safar A, Venter DJ, Munnich A, Ponder BAJ 1994 Diverse phenotypes associated with exon 10 mutations of the RET protooncogene. Hum Mol Genet 3:2163-2167.
16. Ceccherini I, Hofstra RMW, Luo Y, Stulp RP, Barone V, Stelwagen T, Bocciardi R, Nijveen H, Bolino A, Seri M, Ronchetto P, Pasini B, Bozzano M, Buys CHCM, Romeo G 1994 DNA polymorphisms and conditions for SSCP analysis of the 20 exons of the RET proto-oncogene. Oncogene 9:3025-3029.
17. Hofstra RMW, Landsvater RM, Ceccherini I, Stulp RP, Stelwagen T, Luo Y, Pasini B, Hoppener JWM, van Amstel HKP, Romeo G, Lips CJM, Buys CHCM 1994 A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature 367:375-376.
18. Bergholm U, Bergstrom R, Ekborm 1997 A long term follow-up of patients with medullary carcinoma of the thyroid. Cancer 79:132-138.
19. Fuchshuber PR, Loree TR, Hicks WL, Cheney RT, Shedd DR 1998 Medullary carcinoma of the thyroid: prognostic factors and treatment recommendations. Ann Surg Oncol 5:81-86.
20. Gharib H, McConahey WM, Tiegs Rd, Bergstralh EJ, Goellner JR, Grant CS, van Heerden JA, Sizemore GW, Hay ID 1992 Medullary thyroid carcinoma: clinicopathologic features and long-term follow-up of 65 patients treated during 1946 through 1970. Mayo Clin Proc 67:934-940.
21. Scopsi L, Sampietro G, Boracchi Placucci M, Pilotti S 1996 Multivariate analysis of prognostic factors in sporadic medullary carcinoma of the thyroid. A retrospective study of 109 consecutive patients. Cancer 78:2173-2183.
22. Modigliani E, Cohen R, Campos JM, Conte-Devolx B, Maes B, Boneu A, Schlumberger M, Bigorgne JC, Dumontier P, Leclerc L, Corcuff B, Guilhem I 1998 Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. Clin Endocrinol 48:265-273.
23. Dottorini ME, Assi A, Sironi M, Sangalli G, Spreafico G, Colombo L 1996 Multivariate analysis of patients with medullary thyroid carcinoma. Prognostic significance and impact on treatment of clinical and pathologic variables. Cancer 77:1556-1565.
24. Gulben K, Berberoglu U, Boyabath M 2006 Prognostic factors for sporadic medullary thyroid carcinoma. World J Surg 30:84-90.
25. Clark JR, Fridman TR, Odell MJ, Brierley J, Walfish PG, Freeman JL 2005 Prognostic variables and calcitonin in medullary thyroid cancer. Laryngoscope 115:1445-1450.
26. Raue F 1998 German medullary thyroid carcinoma/multiple endocrine neoplasia registry. German MTC/MEN Study Group. Medullary thyroid carcinoma/multiple endocrine neoplasma type 2. Langenbecks Arch Surg 383:334-336.
27. Bergholm U, Adami HO, Bergstrom R, Johansson H, Lundell G, Telenius-Berg M 1989 Clinical characteristics in sporadic and familial medullary thyroid carcinoma: a nationwide study of 249 patients in Sweden from 1959 through 1981. Cancer 73:1196-1204.
28. Chong GC, Beahrs OH, Sizemore GW, Woolner LH 1975 Medullary carcinoma of the thyroid gland. Cancer 35:695-704.
29. Rossi RL, Gady B, Meissner WA, Wool MS, Sedgwick CE, Weber J 1980 Nonfamilial medullary thyroid carcinoma. Am J Surg 139:554-558.
30. Raue F, Kotzerke J, Reinwein D, Schroder S, Roher HD, Deckart H 1993 Prognostic factors in medullary thyroid carcinoma: evaluation of 741 patients from the German Medullary Thyroid Carcinoma Register. Clin Invest 71:7-12.
31. Samaan NA, Schultz PN, Hickey RC 1988 Medullary thyroid carcinoma: prognosis of familial versus sporadic disease and the role of radiotherapy. J Clin Endocrinol Metab 67:801-805.
32. Moley JM, De Benedetti MK 1999 Patterns of nodal metastasis in palpable medullary thyroid carcinoma: recommendations for extent of node dissection. Ann Surg 229:880-888.
33. Scollo C, Baudin E, Travagli BC, Bellon N, Leboulleux S, Schlumberger M 2003 Rationale for central and bilateral lymph node dissection in sporadic and hereditary medullary thyroid cancer. J Clin Endocrinol Metab 88:2070-2075.
34. Pellegriti G, Leboulleux S, Baudin E, Bellon N, Scollo C, Travagli JP, Schlumberger M 2003 Long-term outcome of medullary thyroid carcinoma in patients with normal post-operative medical imaging. Br J Cancer 88:1537-1542.
35. Gimm O, Ukkat J, Dralle H 1998 Determinative factors of biochemical cure after primary and reoperative surgery for sporadic medullary thyroid carcinoma. World J Surg 26:562-567.
36. Kebebew E, Greenspan FS, Clark OH, Woeber KA, Grunwell J 2005 Extent of disease and practice patterns for medullary thyroid cancer. J Am Coll Surg 200:890-896.
37. Weber T, Schilling T, Frank-Raue K, Colombo-Benkmann M, Hinz U, Ziegler R, Klar E 2001 Impact of modified radical neck dissection on biochemical cure in medullary thyroid carcinoma. Surgery 130:1044-1049.
38. Ismailov SI, Piulatova NR 2004 Postoperative calcitonin study in medullary thyroid carcinoma. Endocr Relat Cancer 11:357-363.
39. Barbet J, Campion L, Kraeber-Bodere F, Chatal JF 2005 Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma. J Clin Endocrinol Metab 90:6077-6084.